Decades before he became the world’s wealthiest person and a major supporter of President-elect Donald Trump, tech mogul Elon Musk gained acceptance to a graduate program at Stanford — one he never ...

Tanton, principal investigator of NASA’s Psyche mission, explains in her new book how lessons from interplanetary exploration ...

Young patients can benefit from a trusting relationship with their doctor as it can help them navigate the rollercoaster of ...

Storm chasers record incredible video from inside tornado US-sanctioned tanker tests Trump blockade with Hormuz exit A new restaurant rule is spreading across 11 states — and customers love it Colman ...

Even before the Empire State Building officially opened on May 1, 1931, it represented something greater than just the world’s tallest office building. From the moment of its conception in August 1929 ...

Shanghai-based Tenacia Biotechnology is making a $308 million biobucks move for Rapport Therapeutics' leading asset focused on focal onset seizures (FOS) and primary generalized tonic-clonic seizures, ...

Because I am an experienced negotiator, clients, colleagues, and friends always ask me, “How do you get people to agree with you?” I always tell them that to negotiate effectively, you must understand ...

Alex Honnold again will be ascending without ropes. In an interview he considers the impact on his family if something were to go wrong. Alex Honnold will try to climb a 1,667-foot skyscraper in ...

Rapport building is challenging in pediatric telehealth speech-language services, yet factors influencing it remain unclear. The study specified how patient and clinician factors contributed to the ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Investing in Long-Term Branding to Ensure Resilience and Meet Customer Needs Brand marketers today face a conundrum. Focus too much on short-term brand management to boost sales and long-term brand ...

A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading. The study enrolled 30 ...